A phase II study randomly assigned 73 patients into two groups to receive either the travoprost plug with twice daily artificial tears or timolol 0.5% twice daily with placement of a drug-free punctal plug.
At 90 days, there was a 4.5 to 5.7 mm Hg reduction from baseline IOP in patients who had the travoprost punctal plug, which was clinically meaningful.
However, the control group had an average IOP lowering of 6.4 to 7.6 mm Hg.
“It was thought that the more significant IOP reduction in the control group was explained by longer contact time of the beta blocker on the ocular surface because of the ‘dummy’ plug in the puncta,” Dr. Moster said.
The safety profile was good—no hyperemia was seen. The retention rate at 60, 75, and 90 days was 91%, 88%, and 48%, respectively.
Dr. Moster has no financial interest in the products she discussed.